Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 2/20 | 0.46 |
| ▸ | BCR | P11274 | 2/20 | 0.46 |
| ▸ | RET | P07949 | 2/20 | 0.45 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PLAU | P00749 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2616948 | 0.81 | ABL1 (0.59) | ABL1BCRRETLCKPLA2G7 | |
| Hydrochloric Acid SCHEMBL5548680 | 0.80 | ABL1 (0.58) | ABL1BCRRETLCKPLA2G7 | |
| SCHEMBL17713569 | 0.78 | RET (0.56) | ABL1BCRRETLCKATM | |
| SCHEMBL25394314 | 0.75 | SQOR (0.43) | PLA2G7ATMPLAULMNAHTT | |
| SCHEMBL31387690 | 0.75 | SQOR (0.43) | PLA2G7ATMPLAULMNAHTT | |
| Pyridine SCHEMBL27895751 | 0.75 | ABL1 (0.60) | ABL1BCRRETLCKMEN1 | |
| SCHEMBL25392183 | 0.73 | SQOR (0.44) | PLA2G7ATMLMNAHTTNOS3 | |
| SCHEMBL4733842 | 0.73 | ABL1 (0.67) | ABL1BCRRETLCKCCNB2 | |
| SCHEMBL31387637 | 0.72 | PLA2G7 (0.39) | PLA2G7ATMLMNAHTTNOS3 | |
| SCHEMBL25393426 | 0.72 | PLA2G7 (0.39) | PLA2G7ATMLMNAHTTNOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7638627-B2 | Imatinib hydrochloride; reacting N-(2-methyl-5-aminophenyl-4-(3-pyridyl)-2-pyrimidineamine with 4-(4-methyl-piperazinomethyl)benzoyl chloride; improved reduction step to simplify, increase yield, improve purity | CIPLA LIMITED (IN) | 2009-12-29 | — | — | US | disclosed |
| US-20060173182-A1 | Process of preparing imatinib and imatinib prepared thereby | CIPLA LIMITED (IN) | 2006-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173182-A1 | Process of preparing imatinib and imatinib prepared thereby | ABL1, ABL2, MET | ABL1 1/4885BCR 38/4885RET 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.